Related Experiment Videos
Suppression of experimental autoimmune encephalomyelitis by cannabinoids
I Wirguin1, R Mechoulam, A Breuer
1Department of Neurology, Hadassah University Hospital, Jerusalem, Israel.
Immunopharmacology
|November 1, 1994
Summary
Delta 8-THC, a cannabis compound, effectively reduced EAE symptoms in rats when given orally. This suggests cannabinoids may help manage autoimmune diseases by influencing corticosterone levels.
Area of Science:
- Neuroscience
- Immunology
- Pharmacology
Background:
- Experimental autoimmune encephalomyelitis (EAE) is a model for multiple sclerosis.
- Delta 8-THC is a cannabinoid receptor agonist, similar to delta 9-THC but less psychotropic.
- Cannabinoids are being investigated for their therapeutic potential in autoimmune disorders.
Purpose of the Study:
- To evaluate the efficacy of delta 8-THC in a rat model of EAE.
- To explore the relationship between delta 8-THC administration, neurological deficits, and corticosterone levels.
Main Methods:
- Two strains of rats were induced with EAE.
- Delta 8-THC (40 mg/kg) was administered orally or parenterally for up to 21 days.
- Neurological deficit severity and serum corticosterone levels were measured.
Main Results:
- Oral administration of delta 8-THC significantly decreased EAE incidence and severity.
- Parenteral injection of delta 8-THC did not show beneficial effects.
- Rats treated with delta 8-THC exhibited a twofold increase in serum corticosterone levels.
Conclusions:
- Delta 8-THC demonstrates therapeutic potential for EAE, suggesting a role for cannabinoids in autoimmune disease management.
- The beneficial effects of delta 8-THC appear dependent on oral administration and may be linked to corticosterone modulation.